- Home
- NL vs VCRE Comparison
NL vs VCRE Comparison
Compare NL & VCRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NL | VCRE |
|---|---|---|
| Founded | 1891 | N/A |
| Country | United States | Sweden |
| Employees | N/A | N/A |
| Industry | Major Chemicals | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 283.1M | 332.9M |
| IPO Year | 1994 | 2026 |
Fundamental Metrics
Financial Performance| Metric | NL | VCRE |
|---|---|---|
| Price | $6.89 | $11.07 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 41.0K | 8.0K |
| Earning Date | 05-06-2026 | N/A |
| Dividend Yield | ★ 10.22% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.27 | N/A |
| Revenue | ★ $158,285,000.00 | N/A |
| Revenue This Year | $9.32 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $25.00 | ★ N/A |
| Revenue Growth | ★ 8.46 | N/A |
| 52 Week Low | $5.04 | $10.47 |
| 52 Week High | $8.60 | $13.15 |
Technical Indicators
Market Signals| Indicator | NL | VCRE |
|---|---|---|
| Relative Strength Index (RSI) | 64.35 | 41.47 |
| Support Level | $5.67 | $10.83 |
| Resistance Level | $8.60 | $13.00 |
| Average True Range (ATR) | 0.21 | 0.78 |
| MACD | 0.02 | -0.08 |
| Stochastic Oscillator | 77.11 | 28.73 |
Price Performance
Historical ComparisonAbout NL NL Industries Inc.
NLI Holdings Inc, formerly known as NL Industries Inc, is a holding company that operates in the component products industry. Through its subsidiary, it manufactures engineered components that are sold to a range of industries, including recreational transportation, postal, office and institutional furniture, cabinetry, tool storage, healthcare, gas stations and vending equipment. It also produces a precision ball bearing slide, security products, and ergonomic computer support systems. The company derives majority of its revenue from Europe.
About VCRE Vicore Pharma Holding AB American Depositary Shares
Vicore Pharma Holding AB is a clinical-stage biopharmaceutical company developing a new class of disease-modifying therapies for respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). Its main program, buloxibutid, is an oral angiotensin II type 2 receptor agonist that has received Orphan Drug and Fast Track designation from the U.S. Food and Drug Administration and is currently being evaluated in the 52-week Phase 2b ASPIRE trial in IPF. Currently, Vicore is operating mainly in Sweden.